The DOI matches its Crossref record; 454 of the 454 references it cites were found in a registry or an index.
Radiopharmaceuticals and their applications in medicine
Open accessAbstract
Radiopharmaceuticals involve the local delivery of radionuclides to targeted lesions for the diagnosis and treatment of multiple diseases. Radiopharmaceutical therapy, which directly causes systematic and irreparable damage to targeted cells, has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies. As the Food and Drug Administration (FDA) approvals of [177 Lu]Lu-DOTA-TATE, [177 Lu]Lu-PSMA-617 and their complementary diagnostic agents, namely, [68 Ga]Ga-DOTA-TATE and [68 Ga]Ga-PSMA-11, targeted radiopharmaceutical-based theranostics (radiotheranostics) are being increasingly implemented in clinical practice in oncology, which lead to a new era of radiopharmaceuticals. The new generation of radiopharmaceuticals utilizes a targeting vector to achieve the accurate delivery of radionuclides to lesions and avoid off-target deposition, making it possible to improve the efficiency and biosafety of tumour diagnosis and therapy. Numerous studies have focused on developing novel radiopharmaceuticals targeting a broader range of disease targets, demonstrating remarkable in vivo performance. These include high tumor uptake, prolonged retention time, and favorable pharmacokinetic properties that align with clinical standards. While radiotheranostics have been widely applied in tumor diagnosis and therapy, their applications are now expanding to neurodegenerative diseases, cardiovascular diseases, and inflammation. Furthermore, radiotheranostic-empowered precision medicine is revolutionizing the cancer treatment paradigm. Diagnostic radiopharmaceuticals play a pivotal role in patient stratification and treatment planning, leading to improved therapeutic outcomes in targeted radionuclide therapy. This review offers a comprehensive overview of the evolution of radiopharmaceuticals, including both FDA-approved and clinically investigated agents, and explores the mechanisms of cell death induced by radiopharmaceuticals. It emphasizes the significance and future prospects of theranostic-based radiopharmaceuticals in advancing precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mosmann, T. R., & Coffman, R. L. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.001045 · Cited by 7,692
Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., & Coffman, R. L. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2348 · Cited by 7,506
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
Dalgleish, A. G., Beverley, P. C. L., Clapham, P. R., Crawford, D. H., Greaves, M. F., & Weiss, R. A. (1984) · Nature · doi:10.1038/312763a0 · Cited by 3,533
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T., Gluckman, J.-C., & Montagnier, L. (1984) · Nature · doi:10.1038/312767a0 · Cited by 2,436
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,016
Lymphocyte responses and cytokines
Paul, W. E., & Seder, R. A. (1994) · Cell · doi:10.1016/0092-8674(94)90332-8 · Cited by 1,828
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Interfering with pH regulation in tumours as a therapeutic strategy
Neri, D., & Supuran, C. T. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3554 · Cited by 1,547
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., & Böhlen, P. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90483-2 · Cited by 1,519
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Kratochwil, C., Flechsig, P., Lindner, T., Abderrahim, L., Altmann, A., Mier, W., Adeberg, S., Rathke, H., Röhrich, M., Winter, H., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227967 · Cited by 1,464
Alpha-synuclein and neurodegenerative diseases
Goedert, M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081564 · Cited by 1,408
Regulation of DNA double-strand break repair pathway choice
Shrivastav, M., De Haro, L. P., & Nickoloff, J. A. (2008) · Cell Research · doi:10.1038/cr.2007.111 · Cited by 1,329
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T., & Nijman, H. W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.189 · Cited by 1,277
uPAR: a versatile signalling orchestrator
Blasi, F., & Carmeliet, P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm977 · Cited by 1,223
Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,174
Smith, C. A., Williams, G. T., Kingston, R., Jenkinson, E. J., & Owen, J. J. T. (1989) · Nature · doi:10.1038/337181a0 · Cited by 1,133
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis
Nomura, D. K., Long, J. Z., Niessen, S., Hoover, H. S., Ng, S.-W., & Cravatt, B. F. (2010) · Cell · doi:10.1016/j.cell.2009.11.027 · Cited by 1,002
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
Lindner, T., Loktev, A., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 935
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Bendor, J. T., Logan, T. P., & Edwards, R. H. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.004 · Cited by 825
Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A., Schröder, C. P., Lub-de Hooge, M. N., & de Vries, E. G. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 805
A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
Loktev, A., Lindner, T., Mier, W., Debus, J., Altmann, A., Jäger, D., Giesel, F., Kratochwil, C., Barthe, P., Roumestand, C., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210435 · Cited by 777
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 716
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.
Delbeke, D., Coleman, R. E., Guiberteau, M. J., Brown, M. L., Royal, H. D., Siegel, B. A., Townsend, D. W., Berland, L. L., Parker, J. A., Hubner, K., et al. (2006) · PubMed · Cited by 689
The Intricate Role of CXCR4 in Cancer
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-411638-2.00002-1 · Cited by 672
Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Auger electrons for cancer therapy – a review
Ku, A., Facca, V. J., Cai, Z., & Reilly, R. M. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0075-2 · Cited by 643
Keyt, B. A., Berleau, L. T., Nguyen, H. V., Chen, H., Heinsohn, H., Vandlen, R., & Ferrara, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7788 · Cited by 604
CD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Regulation and mechanisms of mammalian double-strand break repair
Valerie, K., & Povirk, L. F. (2003) · Oncogene · doi:10.1038/sj.onc.1206679 · Cited by 571
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Loktev, A., Lindner, T., Burger, E.-M., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Marmé, F., Jäger, D., Mier, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224469 · Cited by 554
Chen, H., Pang, Y., Wu, J., Zhao, L., Hao, B., Wu, J., Wei, J., Wu, S., Zhao, L., Luo, Z., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04769-z · Cited by 545
Weineisen, M., Schottelius, M., Simecek, J., Baum, R. P., Yildiz, A., Beykan, S., Kulkarni, H. R., Lassmann, M., Klette, I., Eiber, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158550 · Cited by 532
Baum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Mueller, D., Klette, I., & Wester, H.-J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 525
Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O., & Gorrell, M. D. (2014) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300095 · Cited by 496
Integrin trafficking in cells and tissues
Moreno-Layseca, P., Icha, J., Hamidi, H., & Ivaska, J. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0223-z · Cited by 464
Narayanan, P. K., Goodwin, E. H., & Lehnert, B. E. (1997) · PubMed · Cited by 461
Targeted Radionuclide Therapy of Human Tumors
Gudkov, S., Shilyagina, N., Vodeneev, V., & Zvyagin, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010033 · Cited by 456
A review on the clinical uses of SPECT/CT
Mariani, G., Bruselli, L., Kuwert, T., Kim, E. E., Flotats, A., Israel, O., Dondi, M., & Watanabe, N. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1390-8 · Cited by 438
Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain
Choi, S. R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Hefti, F., Benedum, T. E., Kilbourn, M. R., Skovronsky, D., & Kung, H. F. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.065284 · Cited by 431
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Wang, Y., Fei, D., Vanderlaan, M., & Song, A. (2004) · Angiogenesis · doi:10.1007/s10456-004-8272-2 · Cited by 430
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F. P., Gevaert, T., Simon, P., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162024 · Cited by 429
Afshar-Oromieh, A., Hetzheim, H., Kratochwil, C., Benesova, M., Eder, M., Neels, O. C., Eisenhut, M., Kübler, W., Holland-Letz, T., Giesel, F. L., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161299 · Cited by 427
The genomics of oxidative DNA damage, repair, and resulting mutagenesis
Poetsch, A. R. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.12.013 · Cited by 420
Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers
Chauveau, F., Boutin, H., Van Camp, N., Dollé, F., & Tavitian, B. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0908-9 · Cited by 417
Radiotheranostics in oncology: current challenges and emerging opportunities
Bodei, L., Herrmann, K., Schöder, H., Scott, A. M., & Lewis, J. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00652-y · Cited by 414
Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., Hinrichs, M. J. M., Bezabeh, B. Z., Fleming, R. L., Dimasi, N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.008 · Cited by 397
Self-citationPhysics of pure and non-pure positron emitters for PET: a review and a discussion
Conti, M., & Eriksson, L. (2016) · EJNMMI Physics · doi:10.1186/s40658-016-0144-5 · Cited by 393
Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., Baum, R. P., Kunz, P., Hobday, T., Hendifar, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5865 · Cited by 390
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Blodgett, T. M., Meltzer, C. C., & Townsend, D. W. (2007) · Radiology · doi:10.1148/radiol.2422051113 · Cited by 387
PET imaging of inflammation in atherosclerosis
Tarkin, J. M., Joshi, F. R., & Rudd, J. H. F. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.80 · Cited by 386
Emerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
Azzam, E. I., Toledo, S. M. D., Spitz, D. R., & Little, J. B. (2002) · PubMed · Cited by 380
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Marchiò, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.016 · Cited by 377
Sleeboom, J. J. F., van Tienderen, G. S., Schenke-Layland, K., van der Laan, L. J. W., Khalil, A. A., & Verstegen, M. M. A. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3840 · Cited by 375
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
Baum, R. P., Schuchardt, C., Singh, A., Chantadisai, M., Robiller, F. C., Zhang, J., Mueller, D., Eismant, A., Almaguel, F., Zboralski, D., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.259192 · Cited by 359
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Maute, R. L., Gordon, S. R., Mayer, A. T., McCracken, M. N., Natarajan, A., Ring, N. G., Kimura, R., Tsai, J. M., Manglik, A., Kruse, A. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519623112 · Cited by 347
68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
Poeppel, T. D., Binse, I., Petersenn, S., Lahner, H., Schott, M., Antoch, G., Brandau, W., Bockisch, A., & Boy, C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.091165 · Cited by 346
Structural basis of assembly of the human T cell receptor–CD3 complex
Dong, D., Zheng, L., Lin, J., Zhang, B., Zhu, Y., Li, N., Xie, S., Wang, Y., Gao, N., & Huang, Z. (2019) · Nature · doi:10.1038/s41586-019-1537-0 · Cited by 346
Masood, R., Cai, J., Zheng, T., Smith, D. L., Hinton, D. R., & Gill, P. S. (2001) · Blood · doi:10.1182/blood.v98.6.1904 · Cited by 343
Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4144 · Cited by 332
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330
Nelissen, N., Van Laere, K., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M., Bormans, G., Brooks, D. J., & Vandenberghe, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063305 · Cited by 330
Beer, A. J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A. L., Schnell, O., Niemeyer, M., Kessler, H., Wester, H.-J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0266 · Cited by 330
Radiotheranostics: a roadmap for future development
Herrmann, K., Schwaiger, M., Lewis, J. S., Solomon, S. B., McNeil, B. J., Baumann, M., Gambhir, S. S., Hricak, H., & Weissleder, R. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30821-6 · Cited by 327
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response
Larimer, B. M., Wehrenberg-Klee, E., Dubois, F., Mehta, A., Kalomeris, T., Flaherty, K., Boland, G., & Mahmood, U. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3346 · Cited by 325
Hennrich, U., & Eder, M. (2022) · Pharmaceuticals · doi:10.3390/ph15101292 · Cited by 318
CD30: expression and function in health and disease
Horie, R., & Watanabe, T. (1998) · Seminars in Immunology · doi:10.1006/smim.1998.0156 · Cited by 304
Rationale for the use of somatostatin analogs as antitumor agents
Susini, C., & Buscail, L. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl105 · Cited by 304
Radioactive Transition Metals for Imaging and Therapy
Boros, E., & Packard, A. B. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00281 · Cited by 299
Positron emission tomography (PET) imaging with (18)F-based radiotracers.
Alauddin, M. M. (2012) · Europe PMC (PubMed Central) · Cited by 298
Maresca, K. P., Hillier, S. M., Femia, F. J., Keith, D., Barone, C., Joyal, J. L., Zimmerman, C. N., Kozikowski, A. P., Barrett, J. A., Eckelman, W. C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800994j · Cited by 295
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., Honda, N., Kodaira, M., Yamamoto, H., Yunokawa, M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.118612 · Cited by 294
Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer
Hamoudeh, M., Kamleh, M. A., Diab, R., & Fessi, H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.013 · Cited by 283
Zboralski, D., Hoehne, A., Bredenbeck, A., Schumann, A., Nguyen, M., Schneider, E., Ungewiss, J., Paschke, M., Haase, C., von Hacht, J. L., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05842-5 · Cited by 283
Herrmann, K., Schottelius, M., Lapa, C., Osl, T., Poschenrieder, A., Hänscheid, H., Lückerath, K., Schreder, M., Bluemel, C., Knott, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167361 · Cited by 276
Hostetler, E. D., Walji, A. M., Zeng, Z., Miller, P., Bennacef, I., Salinas, C., Connolly, B., Gantert, L., Haley, H., Holahan, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171678 · Cited by 273
Dynamic whole-body PET imaging: principles, potentials and applications
Rahmim, A., Lodge, M. A., Karakatsanis, N. A., Panin, V. Y., Zhou, Y., McMillan, A., Cho, S., Zaidi, H., Casey, M. E., & Wahl, R. L. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4153-6 · Cited by 273
The Structure of the CD4 and CD8 Genes
Littman, D. R. (1987) · Annual Review of Immunology · doi:10.1146/annurev.iy.05.040187.003021 · Cited by 272
Sörensen, J., Sandberg, D., Sandström, M., Wennborg, A., Feldwisch, J., Tolmachev, V., Åström, G., Lubberink, M., Garske-Román, U., Carlsson, J., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131243 · Cited by 258
Immunomodulation by radiotherapy in tumour control and normal tissue toxicity
Cytlak, U. M., Dyer, D. P., Honeychurch, J., Williams, K. J., Travis, M. A., & Illidge, T. M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00568-1 · Cited by 258
Pandit-Taskar, N., Postow, M. A., Hellmann, M. D., Harding, J. J., Barker, C. A., O’Donoghue, J. A., Ziolkowska, M., Ruan, S., Lyashchenko, S. K., Tsai, F., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229781 · Cited by 257
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.
Collins, C., Eary, J. F., Donaldson, G. W., Vernon, C. B., Bush, N. E., Petersdorf, S. H., Livingston, R. B., Gordon, E. E., Chapman, C. R., & Appelbaum, F. R. (1993) · PubMed · Cited by 254
Onwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14122-0 · Cited by 243
Johnbeck, C. B., Knigge, U., Loft, A., Berthelsen, A. K., Mortensen, J., Oturai, P., Langer, S. W., Elema, D. R., & Kjaer, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.180430 · Cited by 243
Kudo, Y., Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K., Maruyama, M., Itoh, M., Iwata, R., Yanai, K., & Arai, H. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037556 · Cited by 242
JACC: Cardiovascular Imaging 2.0
Chandrashekhar, Y., & Fuster, V. (2018) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2018.03.005 · Cited by 241
Therapeutic radionuclides in nuclear medicine: current and future prospects
Yeong, C.-H., Cheng, M.-H., & Ng, K.-H. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1400131 · Cited by 239
Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies
Heskamp, S., Hobo, W., Molkenboer-Kuenen, J. D. M., Olive, D., Oyen, W. J. G., Dolstra, H., & Boerman, O. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3477 · Cited by 234
Introduction to Radiobiology of Targeted Radionuclide Therapy
Pouget, J.-P., Lozza, C., Deshayes, E., Boudousq, V., & Navarro-Teulon, I. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00012 · Cited by 232
PET of CXCR4 Expression by a 68Ga-Labeled Highly Specific Targeted Contrast Agent
Gourni, E., Demmer, O., Schottelius, M., D'Alessandria, C., Schulz, S., Dijkgraaf, I., Schumacher, U., Schwaiger, M., Kessler, H., & Wester, H.-J. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098798 · Cited by 228
Zürcher, N. R., Loggia, M. L., Lawson, R., Chonde, D. B., Izquierdo-Garcia, D., Yasek, J. E., Akeju, O., Catana, C., Rosen, B. R., Cudkowicz, M. E., et al. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.01.009 · Cited by 226
Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S., & Joshua, A. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0078-9 · Cited by 225
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Singh, P., Toom, S., & Huang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0473-4 · Cited by 224
Kuten, J., Fahoum, I., Savin, Z., Shamni, O., Gitstein, G., Hershkovitz, D., Mabjeesh, N. J., Yossepowitch, O., Mishani, E., & Even-Sapir, E. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234187 · Cited by 224
The promise of targeted {alpha}-particle therapy.
Mulford, D. A., Scheinberg, D. A., & Jurcic, J. G. (2005) · PubMed · Cited by 223
Philipp‐Abbrederis, K., Herrmann, K., Knop, S., Schottelius, M., Eiber, M., Lückerath, K., Pietschmann, E., Habringer, S., Gerngroß, C., Franke, K., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404698 · Cited by 221
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
Mansi, R., Wang, X., Forrer, F., Waser, B., Cescato, R., Graham, K., Borkowski, S., Reubi, J. C., & Maecke, H. R. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1596-9 · Cited by 205
Self-citationSamanta, D., & Almo, S. C. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1763-4 · Cited by 205
Ikawa, M., Lohith, T. G., Shrestha, S., Telu, S., Zoghbi, S. S., Castellano, S., Taliani, S., Da Settimo, F., Fujita, M., Pike, V. W., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178996 · Cited by 195
Covalent targeted radioligands potentiate radionuclide therapy
Cui, X.-Y., Li, Z., Kong, Z., Liu, Y., Meng, H., Wen, Z., Wang, C., Chen, J., Xu, M., Li, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07461-6 · Cited by 195
Rowe, C. C., Pejoska, S., Mulligan, R. S., Jones, G., Chan, J. G., Svensson, S., Cselényi, Z., Masters, C. L., & Villemagne, V. L. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114785 · Cited by 191
Ulaner, G. A., Hyman, D. M., Ross, D. S., Corben, A., Chandarlapaty, S., Goldfarb, S., McArthur, H., Erinjeri, J. P., Solomon, S. B., Kolb, H., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.172031 · Cited by 191
Mueller, A., Bullich, S., Barret, O., Madonia, J., Berndt, M., Papin, C., Perrotin, A., Koglin, N., Kroth, H., Pfeifer, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236224 · Cited by 191
In vivo quantification of neurofibrillary tangles with [18F]MK-6240
Pascoal, T. A., Shin, M., Kang, M. S., Chamoun, M., Chartrand, D., Mathotaarachchi, S., Bennacef, I., Therriault, J., Ng, K. P., Hopewell, R., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0402-y · Cited by 186
Delpassand, E. S., Tworowska, I., Esfandiari, R., Torgue, J., Hurt, J., Shafie, A., & Núñez, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263230 · Cited by 186
Carrasquillo, J. A., O’Donoghue, J. A., Pandit-Taskar, N., Humm, J. L., Rathkopf, D. E., Slovin, S. F., Williamson, M. J., Lacuna, K., Aksnes, A.-K., Larson, S. M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2427-6 · Cited by 185
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Hennrich, U., & Benešová, M. (2020) · Pharmaceuticals · doi:10.3390/ph13030038 · Cited by 184
Recent developments on PET radiotracers for TSPO and their applications in neuroimaging
Zhang, L., Hu, K., Shao, T., Hou, L., Zhang, S., Ye, W., Josephson, L., Meyer, J. H., Zhang, M.-R., Vasdev, N., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.006 · Cited by 184
Self-citationWong, P. F., Wei, W., Smithy, J. W., Acs, B., Toki, M. I., Blenman, K. R. M., Zelterman, D., Kluger, H. M., & Rimm, D. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2652 · Cited by 182
Smith, R. A., Capotosti, F., Schain, M., Ohlsson, T. G., Vokali, E., Molette, J., Touilloux, T., Hliva, V., Dimitrakopoulos, I. K., Puschmann, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42305-3 · Cited by 181
Ulaner, G. A., Lyashchenko, S. K., Riedl, C., Ruan, S., Zanzonico, P. B., Lake, D., Jhaveri, K., Zeglis, B., Lewis, J. S., & O’Donoghue, J. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202010 · Cited by 179
Mansi, R., Wang, X., Forrer, F., Kneifel, S., Tamma, M.-L., Waser, B., Cescato, R., Reubi, J. C., & Maecke, H. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3145 · Cited by 178
Self-citationHamelin, L., Lagarde, J., Dorothée, G., Potier, M. C., Corlier, F., Kuhnast, B., Caillé, F., Dubois, B., Fillon, L., Chupin, M., et al. (2018) · Brain · doi:10.1093/brain/awy079 · Cited by 177
Ploug, M., Østergaard, S., Gårdsvoll, H., Kovalski, K., Holst-Hansen, C., Holm, A., Ossowski, L., & Danø, K. (2001) · Biochemistry · doi:10.1021/bi010662g · Cited by 176
Review on 99mTc radiopharmaceuticals with emphasis on new advancements
Duatti, A. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.05.005 · Cited by 174
Bioorthogonal chemistry for prodrug activation in vivo
Fu, Q., Shen, S., Sun, P., 谷, 知., Bai, Y., Wang, X., & Liu, Z. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00889k · Cited by 173
Self-citationICOS+ Tregs: A Functional Subset of Tregs in Immune Diseases
Li, D.-Y., & Xiong, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02104 · Cited by 172
Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of68Ga-Labeled FAPI Dimer
Zhao, L., Niu, B., Fang, J., Pang, Y., Li, S., Xie, C., Sun, L., Zhang, X., Guo, Z., Lin, Q., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263016 · Cited by 169
Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer
de Bock, C. E., & Wang, Y. (2003) · Medicinal Research Reviews · doi:10.1002/med.10054 · Cited by 167
Predicting tumour radiosensitivity to deliver precision radiotherapy
Price, J. M., Prabhakaran, A., & West, C. M. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00709-y · Cited by 167
Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies
Xiang, J., Tao, Y., Xia, Y., Luo, S., Zhao, Q., Li, B., Zhang, X., Sun, Y., Xia, W., Zhang, M., et al. (2023) · Cell · doi:10.1016/j.cell.2023.06.004 · Cited by 165
Self-citationScarf, A. M., & Kassiou, M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.086629 · Cited by 164
Josefsson, A., Nedrow, J. R., Park, S., Banerjee, S. R., Rittenbach, A., Jammes, F., Tsui, B., & Sgouros, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2141 · Cited by 164
Peptide‐mediated targeted drug delivery
Majumdar, S., & Siahaan, T. J. (2010) · Medicinal Research Reviews · doi:10.1002/med.20225 · Cited by 163
Ma, H., Li, C., Wang, J., Zhang, X., Li, M., Zhang, R., Huang, Z., & Zhang, Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019409118 · Cited by 161
Pugliese, F., Gaemperli, O., Kinderlerer, A. R., Lamare, F., Shalhoub, J., Davies, A. H., Rimoldi, O. E., Mason, J. C., & Camici, P. G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.063 · Cited by 158
Laforest, R. A., Lapi, S. E., Oyama, R., Bose, R., Tabchy, A. B., Marquez-Nostra, B. V., Bartels, J. L., Wright, B. D., Frye, J., Frye, S. A., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0951-z · Cited by 158
PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET
Lesniak, W. G., Chatterjee, S., Gabrielson, M., Lisok, A., Wharram, B. L., Pomper, M. G., & Nimmagadda, S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00348 · Cited by 158
Kurth, J., Krause, B. J., Schwarzenböck, S. M., Bergner, C., Hakenberg, O. W., & Heuschkel, M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04504-3 · Cited by 157
Imaging activated T cells predicts response to cancer vaccines
Alam, I. S., Mayer, A. T., Sagiv-Barfi, I., Wang, K., Vermesh, O., Czerwinski, D. K., Johnson, E. M., James, M. L., Levy, R., & Gambhir, S. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98509 · Cited by 156
Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
Jie, C. V. M. L., Treyer, V., Schibli, R., & Mu, L. (2021) · Pharmaceuticals · doi:10.3390/ph14020110 · Cited by 155
Mojtahedi, A., Thamake, S. I., Tworowska, I., Ranganathan, D., & Delpassand, E. S. (2014) · Europe PMC (PubMed Central) · Cited by 153
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
Jones, W. E., Griffiths, K., Barata, P. C., & Paller, C. J. (2020) · Cancers · doi:10.3390/cancers12061367 · Cited by 148
Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
de Ruijter, L. K., van de Donk, P. P., Hooiveld-Noeken, J. S., Giesen, D., Elias, S. G., Hooge, M. N. L., Oosting, S. F., Jalving, M., Timens, W., Brouwers, A. H., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02084-8 · Cited by 147
Therapeutic radionuclides and nuclear data
Qaim, S. M. (2001) · Radiochimica Acta · doi:10.1524/ract.2001.89.4-5.297 · Cited by 146
Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases
Weng, T.-Y., Tsai, S., & Su, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0380-6 · Cited by 146
Radiotheranostics in Cancer Diagnosis and Management
Jadvar, H., Chen, X. S., Cai, W., & Mahmood, U. (2018) · Radiology · doi:10.1148/radiol.2017170346 · Cited by 146
Self-citationNewberg, A. B., Wintering, N., Plößl, K., Hochold, J., Stabin, M. G., Watson, M., Skovronsky, D., Clark, C. M., Kung, M., & Kung, H. F. (2006) · PubMed · Cited by 143
Dalm, S. U., Nonnekens, J., Doeswijk, G. N., de Blois, E., van Gent, D. C., Konijnenberg, M., & de Jong, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167007 · Cited by 143
Kaufman, N. E. M., Dhingra, S., Jois, S. D. S., & Vicente, M. G. H. (2021) · Molecules · doi:10.3390/molecules26041076 · Cited by 143
Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer
Silva, R. A. D., Kumar, D., Lisok, A., Chatterjee, S., Wharram, B. L., Rao, K. V., Mease, R. C., Dannals, R. F., Pomper, M. G., & Nimmagadda, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00399 · Cited by 142
The Sodium Iodide Symporter and Its Potential Role in Cancer Therapy
Spitzweg, C., Harrington, K. J., PINKE, L. A., Vile, R. G., & Morris, J. C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7641 · Cited by 141
Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale
Rowe, C. C., Jones, G. R., Doré, V., Pejoska, S., Margison, L., Mulligan, R. S., Chan, J. G., Young, K., & Villemagne, V. L. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171595 · Cited by 141
Radium-223 mechanism of action: implications for use in treatment combinations
Morris, M. J., Corey, E., Guise, T. A., Gulley, J. L., Kelly, W. K., Quinn, D. I., Scholz, A., & Sgouros, G. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0251-x · Cited by 140
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors
van Egmond, N., Straub, V. M., & van der Stelt, M. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-112741 · Cited by 139
Naganawa, M., Li, S., Nabulsi, N., Henry, S., Zheng, M.-Q., Pracitto, R., Cai, Z., Gao, H., Kapinos, M., Labaree, D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.249144 · Cited by 138
Bouchard, P., & Quirion, R. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00221-7 · Cited by 137
Okamura, N., Villemagne, V. L., Drago, J., Pejoska, S., Dhamija, R. K., Mulligan, R. S., Ellis, J. R., Ackermann, U., O'Keefe, G. J., Jones, G. R., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.070094 · Cited by 136
Zhou, X. M., Jiang, J., Yang, X., Liu, T., Ding, J., Nimmagadda, S., Pomper, M. G., Zhu, H., Zhao, J., Yang, Z., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262045 · Cited by 135
Procedure guideline for therapy of thyroid disease with (131)iodine.
Meier, D. A., Brill, D., Becker, D. V., Clarke, S. E., Silberstein, E. B., Royal, H. D., & Balon, H. R. (2002) · PubMed · Cited by 134
Suridjan, I., Pollock, B. G., Verhoeff, N. P. L. G., Voineskos, A. N., Chow, T., Rusjan, P. M., Lobaugh, N. J., Houle, S., Mulsant, B. H., & Mizrahi, R. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.1 · Cited by 132
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging
Ulaner, G. A., Sobol, N. B., O’Donoghue, J. A., Kirov, A. S., Riedl, C. C., Min, R., Smith, E., Carter, L. M., Lyashchenko, S. K., Lewis, J. S., et al. (2020) · Radiology · doi:10.1148/radiol.2020192621 · Cited by 132
Radiotheranostics in oncology: Making precision medicine possible
Aboagye, E. O., Barwick, T. D., & Haberkorn, U. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21768 · Cited by 131
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy
Larimer, B. M., Wehrenberg-Klee, E. P., Caraballo, A., & Mahmood, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.173930 · Cited by 131
Li, S., Cai, Z., Wu, X., Holden, D., Pracitto, R., Kapinos, M., Gao, H., Labaree, D. C., Nabulsi, N., Carson, R. E., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00526 · Cited by 130
Radionuclides for Targeted Therapy: Physical Properties
Stokke, C., Kvassheim, M., & Blakkisrud, J. (2022) · Molecules · doi:10.3390/molecules27175429 · Cited by 130
Fu, H., Huang, J., Zhao, T., Wang, H., Chen, Y., Xu, W., Pang, Y., Guo, W., Sun, L., Wu, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1983 · Cited by 130
Self-citationHamano, T., Enomoto, S., Shirafuji, N., Ikawa, M., Yamamura, O., Yen, S.-H. C., & Nakamoto, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147475 · Cited by 127
Pang, Y., Zhao, L., Meng, T., Xu, W., Lin, Q., Wu, H., Zhang, J., Chen, X. S., Sun, L., & Chen, H. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264544 · Cited by 126
Self-citationSalih, S., Alkatheeri, A., Alomaim, W., & Elliyanti, A. (2022) · Molecules · doi:10.3390/molecules27165231 · Cited by 125
D’Huyvetter, M., Vos, J. D., Caveliers, V., Vaneycken, I., Heemskerk, J., Duhoux, F. P., Fontaine, C., Vanhoeij, M., Windhorst, A. D., van der Aa, F., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.255679 · Cited by 124
Chen, H., Zhao, L., Fu, K., Lin, Q., Wen, X., Jacobson, O., Sun, L., Wu, H., Zhang, X., Guo, Z., et al. (2019) · Theranostics · doi:10.7150/thno.39203 · Cited by 123
Self-citationNoninvasive PET Imaging of T cells
Wei, W., Jiang, D., Ehlerding, E. B., Luo, Q., & Cai, W. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.03.009 · Cited by 122
Radioimmunotherapy with α-Particle Emitting Radioimmunoconjugates
Zalutsky, M. R., & Bigner, D. D. (1996) · Acta Oncologica · doi:10.3109/02841869609101654 · Cited by 121
Normandin, M. D., Petersen, K. F., Ding, Y., Lin, S.-F., Naik, S., Fowles, K., Skovronsky, D., Herold, K. C., McCarthy, T. J., Calle, R. A., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.100545 · Cited by 120
18F-FDOPA: A Multiple-Target Molecule
Minn, H. R. I., Kauhanen, S. P., Seppänen, M., & Nuutila, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.065664 · Cited by 119
ICOS Is an Indicator of T-cell–Mediated Response to Cancer Immunotherapy
Xiao, Z., Mayer, A. T., Nobashi, T. W., & Gambhir, S. S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3265 · Cited by 119
First-in-human uPAR PET: Imaging of Cancer Aggressiveness
Persson, M., Skovgaard, D. C., Brandt-Larsen, M., Christensen, C. L., Madsen, J., Nielsen, C. H., Thurison, T., Klausen, T. L., Holm, S., Loft, A., et al. (2015) · Theranostics · doi:10.7150/thno.12956 · Cited by 118
Guo, Q., Colasanti, A., Owen, D. R., Ónega, M., Kamalakaran, A., Bennacef, I., Matthews, P., Rabiner, E., Turkheimer, F., & Gunn, R. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.121020 · Cited by 117
Ersahin, D., Doddamane, I., & Cheng, D. (2011) · Cancers · doi:10.3390/cancers3043838 · Cited by 116
Cescato, R., Érchegyi, J., Waser, B., Piccand, V., Maëcke, H. R., Rivier, J., & Reubi, J. C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701618q · Cited by 116
Schnell, R., Dietlein, M., Staak, J. O., Borchmann, P., Schomaecker, K., Fischer, T. H., Eschner, W., Hansen, H. P., Morschhauser, F., Schicha, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.098 · Cited by 116
Verhoeff, S. R., van Es, S. C., Boon, E., Helden, E. J. V., Angus, L., Elias, S. G., Oosting, S. F., Aarntzen, E. H. J. G., Brouwers, A. H., Kwee, T. C., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04358-9 · Cited by 116
Papadimitroulas, P., Loudos, G. K., Nikiforidis, G. C., & Kagadis, G. C. (2012) · Medical Physics · doi:10.1118/1.4737096 · Cited by 115
Metadata
- Authors
- Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-01-03
- Volume
- 10
- Issue
- 1
- Pages
- 1-1
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4406003699
- Cited by
- 284
- References
- 454
- FWCI
- 151.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.